Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases

Inclusion Criteria: * Biopsy-proved pancreatic adenocarcinoma with synchronous liver metastases * Elevated Cancer Antigen 19-9 (CA19-9) at diagnosis (\>37 U/mL) * Ages 18-75 years * Karnofsky performance status ≥70 * Ability to undergo general anesthesia and HAI pump placement procedure * CT or MRI scan imaging of the abdomen demonstrating accessibility of the gastroduodenal artery within 2 months of enrollment * Received a minimum of 2 months of systemic chemotherapy with stable tumor markers and imaging. Exclusion Criteria: * Primary tumor resected * Model for End Stage Liver Disease (MELD) score \>20, using the variables of: Bilirubin, serum Sodium, International Normalized Ratio (INR), serum Creatinine, and Dialysis twice in the past week. * Greater than 60% liver parenchymal involvement by tumor * Evidence of peritoneal metastases * Current alcohol abuse * Pregnant or lactating women